Qiagen N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
28 okt 2015 - 21:05
Statutaire naam
Qiagen N.V.
Titel
QIAGEN reports results for third quarter and first nine months of 2015
Bericht
• Q3 2015: Adjusted net sales $315 million (+2% CER, -7% reported); adjusted operating income $78 million; adjusted EPS $0.27 ($0.29 CER)
o Adjusted net sales rise about 5% CER excluding approximately three percentage points of headwind from reduced U.S. HPV test sales
• First nine months 2015: Adjusted net sales $933 million (+3% CER, -5% reported); adjusted operating income $225 million; adjusted EPS $0.74 ($0.81 CER)
o Free cash flow rises 10% to $163 million
• Growth drivers continue to lead solid underlying performance in 2015, providing about one-third of sales and advancing at a double-digit CER pace
• QIAGEN reaffirms full-year 2015 expectations for higher adjusted net sales and earnings at CER; adverse impact on reported results from currency movements
Gerelateerde downloads
Datum laatste update: 12 juli 2025